title: [Could nafamostat or gabexate prevent the post endoscopic retrograde cholangiopancreatography pancreatitis?].
abstract: OBJECTIVE
  ERCP is the most common procedure for the diagnosis and treatment of bile duct and pancreatic disease, but Post-ERCP pancreatitis makes poor outcome in some cases. The protease inhibitors, nafamostat and gabexate, have been used to prevent pancreatitis related to ERCP, but there is some debate. We tried to evaluate the efficacy of gabexate and nafamostat for the prevention of post-ERCP pancreatitis.
  
  
  METHODS
  Two hundred forty two patients (73 patients in the gabexate group, 88 patients in the nafamostat group and 81 patients in the placebo group) were included in the study after selective exclusion. The incidence of pancreatitis after ERCP was compared among groups.
  
  
  RESULTS
  The incidence of pancreatitis were 6.8% in the gabexate group, 5.7% in the nafamostat group and 6.2% in the placebo group (p=0.954).
  
  
  CONCLUSIONS
  There was no meaningful difference among the gabexate, nafamostat and placebo group.
authors.affiliation: Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
authors.forename: Yong Hwan
authors.initials: YH
authors.lastname: Kwon
authors.forename: Ji Yeon
authors.initials: JY
authors.lastname: Kim
authors.forename: Sang Jik
authors.initials: SJ
authors.lastname: Lee
authors.forename: Se Young
authors.initials: SY
authors.lastname: Jang
authors.forename: Hyun Woo
authors.initials: HW
authors.lastname: Park
authors.forename: Hae Min
authors.initials: HM
authors.lastname: Yang
authors.forename: Min Kyu
authors.initials: MK
authors.lastname: Jung
authors.forename: Seong Woo
authors.initials: SW
authors.lastname: Jeon
authors.forename: Chang Min
authors.initials: CM
authors.lastname: Cho
authors.forename: Won Young
authors.initials: WY
authors.lastname: Tak
authors.forename: Young Oh
authors.initials: YO
authors.lastname: Kweon
authors.forename: Sung Kook
authors.initials: SK
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001550:Benzamidines; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D005260:Female; D016670:Gabexate / Q000627:therapeutic use*; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000209:etiology / Q000517:prevention & control*; D015990:Placebo Effect; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D001550:Benzamidines; D006146:Guanidines; D015842:Serine Proteinase Inhibitors; D016670:Gabexate; C032855:nafamostat